Supernus Pharmaceuticals SUPN Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 89.6%+1.4pp | 88.2%+2.0pp | 86.2%-0.7pp | 86.9%-0.1pp | |
| Operating margin | -8.7%-21.0pp | 12.3%+13.2pp | -0.9%-7.8pp | 6.9%-7.9pp | |
| Net margin | -5.4%-16.5pp | 11.2%+10.9pp | 0.2%-8.9pp | 9.1%-0.1pp | |
| Returns | |||||
| Return on equity | -3.7%-11.2pp | 7.5%+7.4pp | 0.1%-7.0pp | 7.1%+0.3pp | |
| Return on invested capital | -6.3%-12.8pp | 6.5%+7.1pp | -0.6%-5.5pp | 4.9%-3.1pp | |
| Efficiency | |||||
| Asset turnover | 0.5×0.0× | 0.5×+0.1× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | |||||
| Current ratio | 1.9×-0.4× | 2.3×+0.6× | 1.7×+0.6× | 1.1×-0.8× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×-0.5× | |
| Net debt / EBITDA | -3×-2.8× | -0.2×+0.2× | -0.4×0.0× | -0.4×-2.3× | |
| Per Share | |||||
| Book value per share | $18.81+1.6% | $18.51+11.5% | $16.60+15.5% | $14.37-4.3% | |
| Valuation | |||||
| Market capitalization | $2.85B+42.7% | $2B+26.3% | $1.58B-18.1% | $1.93B+11.5% | |
| Price / sales | 4×+0.9× | 3×+0.4× | 2.6×-0.3× | 2.9×-0.1× | |
| Price / book | 2.7×+0.8× | 1.9×+0.2× | 1.7×-0.5× | 2.2×+0.1× | |
| EV / EBITDA | 94.3×+82.2× | 12.1×-7.3× | 19.4×+5.2× | 14.3×-2.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Supernus Pharmaceuticals's profit margins?
- Supernus Pharmaceuticals (SUPN) runs a 89.4% gross margin and a -7.8% operating margin, with a -3.7% net margin.
- Where do Supernus Pharmaceuticals's ratios come from?
- Every ratio is computed from Supernus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
